Cargando…

Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

BACKGROUND: Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of no...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueyama, Hideki, Ohta, Yoichi, Imai, Yuuki, Suzuki, Akinobu, Sugama, Ryo, Minoda, Yukihide, Takaoka, Kunio, Nakamura, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819170/
https://www.ncbi.nlm.nih.gov/pubmed/33472600
http://dx.doi.org/10.1186/s12891-021-03971-w
_version_ 1783638959070380032
author Ueyama, Hideki
Ohta, Yoichi
Imai, Yuuki
Suzuki, Akinobu
Sugama, Ryo
Minoda, Yukihide
Takaoka, Kunio
Nakamura, Hiroaki
author_facet Ueyama, Hideki
Ohta, Yoichi
Imai, Yuuki
Suzuki, Akinobu
Sugama, Ryo
Minoda, Yukihide
Takaoka, Kunio
Nakamura, Hiroaki
author_sort Ueyama, Hideki
collection PubMed
description BACKGROUND: Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of not only osteoblast precursor cells but also osteoclast precursor cells. The present study aimed to induce and maintain new bone formation using the topical co-administration of recombinant human BMP-2 (rh-BMP-2) and zoledronate (ZOL) on beta-tricalcium phosphate (β-TCP) composite. METHODS: β-TCP columns were impregnated with both rh-BMP-2 (30 µg) and ZOL (5 µg), rh-BMP-2 alone, or ZOL alone, and implanted into the left femur canal of New Zealand white rabbits (n = 56). The implanted β-TCP columns were harvested and evaluated at 3 and 6 weeks after implantation. These harvested β-TCP columns were evaluated radiologically using plane radiograph, and histologically using haematoxylin/eosin (H&E) and Masson’s trichrome (MT) staining. In addition, micro-computed tomography (CT) was performed for qualitative analysis of bone formation in each group (n = 7). RESULTS: Tissue sections stained with H&E and MT dyes revealed that new bone formation inside the β-TCP composite was significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). Micro-CT data also demonstrated that the bone volume and the bone mineral density inside the β-TCP columns were significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). CONCLUSIONS: The topical co-administration of both rh-BMP-2 and ZOL on β-TCP composite promoted and maintained newly formed bone structure in the bone marrow environment.
format Online
Article
Text
id pubmed-7819170
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78191702021-01-22 Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment Ueyama, Hideki Ohta, Yoichi Imai, Yuuki Suzuki, Akinobu Sugama, Ryo Minoda, Yukihide Takaoka, Kunio Nakamura, Hiroaki BMC Musculoskelet Disord Research Article BACKGROUND: Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of not only osteoblast precursor cells but also osteoclast precursor cells. The present study aimed to induce and maintain new bone formation using the topical co-administration of recombinant human BMP-2 (rh-BMP-2) and zoledronate (ZOL) on beta-tricalcium phosphate (β-TCP) composite. METHODS: β-TCP columns were impregnated with both rh-BMP-2 (30 µg) and ZOL (5 µg), rh-BMP-2 alone, or ZOL alone, and implanted into the left femur canal of New Zealand white rabbits (n = 56). The implanted β-TCP columns were harvested and evaluated at 3 and 6 weeks after implantation. These harvested β-TCP columns were evaluated radiologically using plane radiograph, and histologically using haematoxylin/eosin (H&E) and Masson’s trichrome (MT) staining. In addition, micro-computed tomography (CT) was performed for qualitative analysis of bone formation in each group (n = 7). RESULTS: Tissue sections stained with H&E and MT dyes revealed that new bone formation inside the β-TCP composite was significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). Micro-CT data also demonstrated that the bone volume and the bone mineral density inside the β-TCP columns were significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). CONCLUSIONS: The topical co-administration of both rh-BMP-2 and ZOL on β-TCP composite promoted and maintained newly formed bone structure in the bone marrow environment. BioMed Central 2021-01-20 /pmc/articles/PMC7819170/ /pubmed/33472600 http://dx.doi.org/10.1186/s12891-021-03971-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ueyama, Hideki
Ohta, Yoichi
Imai, Yuuki
Suzuki, Akinobu
Sugama, Ryo
Minoda, Yukihide
Takaoka, Kunio
Nakamura, Hiroaki
Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
title Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
title_full Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
title_fullStr Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
title_full_unstemmed Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
title_short Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
title_sort topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819170/
https://www.ncbi.nlm.nih.gov/pubmed/33472600
http://dx.doi.org/10.1186/s12891-021-03971-w
work_keys_str_mv AT ueyamahideki topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment
AT ohtayoichi topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment
AT imaiyuuki topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment
AT suzukiakinobu topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment
AT sugamaryo topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment
AT minodayukihide topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment
AT takaokakunio topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment
AT nakamurahiroaki topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment